Skip to main content
NASDAQ:CALA

Calithera Biosciences News Headlines

$2.19
+0.03 (+1.39 %)
(As of 05/18/2021 03:59 PM ET)
Add
Compare
Today's Range
$2.12
$2.27
50-Day Range
$1.96
$2.50
52-Week Range
$1.87
$7.03
Volume62,025 shs
Average Volume1.45 million shs
Market Capitalization$162.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Headlines

Calithera Biosciences (NASDAQ CALA) News Headlines Today

SourceHeadline
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
sg.finance.yahoo.com - May 17 at 12:56 PM
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
finance.yahoo.com - May 17 at 12:56 PM
Critical Comparison: Calithera Biosciences (NASDAQ:CALA) versus United Therapeutics (NASDAQ:UTHR)Critical Comparison: Calithera Biosciences (NASDAQ:CALA) versus United Therapeutics (NASDAQ:UTHR)
americanbankingnews.com - May 16 at 8:14 PM
 Brokerages Expect Calithera Biosciences, Inc. (NASDAQ:CALA) Will Post Earnings of -$0.22 Per Share Brokerages Expect Calithera Biosciences, Inc. (NASDAQ:CALA) Will Post Earnings of -$0.22 Per Share
americanbankingnews.com - May 11 at 5:18 PM
Calithera Biosciences (NASDAQ:CALA) Earns Buy Rating from HC WainwrightCalithera Biosciences (NASDAQ:CALA) Earns Buy Rating from HC Wainwright
americanbankingnews.com - May 10 at 8:36 AM
Calithera Biosciences (NASDAQ:CALA) Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPSCalithera Biosciences (NASDAQ:CALA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
americanbankingnews.com - May 8 at 6:54 PM
Calithera Biosciences Inc (CALA) Q1 2021 Earnings Call TranscriptCalithera Biosciences Inc (CALA) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 7:33 PM
Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent HighlightsCalithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
finance.yahoo.com - May 6 at 6:29 PM
Calithera Biosciences, Inc. (NASDAQ:CALA) Short Interest UpdateCalithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Update
americanbankingnews.com - May 3 at 10:26 AM
Calithera Biosciences (CALA) Scheduled to Post Earnings on ThursdayCalithera Biosciences (CALA) Scheduled to Post Earnings on Thursday
americanbankingnews.com - May 1 at 8:24 AM
Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
finance.yahoo.com - April 30 at 7:06 AM
Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual MeetingResults from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting
finance.yahoo.com - April 28 at 7:37 AM
Zacks: Brokerages Anticipate Calithera Biosciences, Inc. (NASDAQ:CALA) to Announce -$0.27 EPSZacks: Brokerages Anticipate Calithera Biosciences, Inc. (NASDAQ:CALA) to Announce -$0.27 EPS
americanbankingnews.com - April 24 at 4:26 AM
Could The Calithera Biosciences, Inc. (NASDAQ:CALA) Ownership Structure Tell Us Something Useful?Could The Calithera Biosciences, Inc. (NASDAQ:CALA) Ownership Structure Tell Us Something Useful?
nasdaq.com - April 9 at 11:05 PM
Were Keeping An Eye On Calithera Biosciences (NASDAQ:CALA) Cash Burn RateWe're Keeping An Eye On Calithera Biosciences' (NASDAQ:CALA) Cash Burn Rate
finance.yahoo.com - March 29 at 8:59 AM
Calithera Biosciences Inc (CALA) Q4 2020 Earnings Call TranscriptCalithera Biosciences Inc (CALA) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 25 at 1:55 AM
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call TranscriptCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 18 at 5:07 AM
Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent HighlightsCalithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights
finance.yahoo.com - March 16 at 8:31 PM
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021
finance.yahoo.com - March 12 at 3:50 PM
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
finance.yahoo.com - March 10 at 7:29 AM
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 ConferenceCalithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
finance.yahoo.com - March 2 at 7:15 AM
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceCalithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 22 at 9:15 AM
Implied Volatility Surging for Calithera Biosciences (CALA) Stock OptionsImplied Volatility Surging for Calithera Biosciences (CALA) Stock Options
finance.yahoo.com - January 13 at 2:49 PM
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat FailsCalithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
finance.yahoo.com - January 5 at 1:29 PM
Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 ConferenceCalithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
finance.yahoo.com - January 5 at 8:29 AM
Why Is It Moving? Analyzing The Downward Movement in Calithera Biosciencess Stock TodayWhy Is It Moving? Analyzing The Downward Movement in Calithera Biosciences's Stock Today
msn.com - January 4 at 2:23 PM
Stock Alert: Calithera Biosciences Tanks 40%Stock Alert: Calithera Biosciences Tanks 40%
nasdaq.com - January 4 at 2:23 PM
Why Calithera Biosciences Stock Is Plunging TodayWhy Calithera Biosciences Stock Is Plunging Today
finance.yahoo.com - January 4 at 2:23 PM
Calithera Biosciences CANTATA Trial Fails To Achieve Primary Endpoint - Quick FactsCalithera Biosciences' CANTATA Trial Fails To Achieve Primary Endpoint - Quick Facts
nasdaq.com - January 4 at 9:22 AM
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary EndpointCalithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
finance.yahoo.com - January 4 at 9:22 AM
Our Take On Calithera Biosciences (NASDAQ:CALA) CEO SalaryOur Take On Calithera Biosciences' (NASDAQ:CALA) CEO Salary
finance.yahoo.com - December 29 at 7:59 AM
CALA Jan 2021 10.000 putCALA Jan 2021 10.000 put
uk.finance.yahoo.com - December 28 at 12:26 AM
CALA Jan 2021 10.000 callCALA Jan 2021 10.000 call
uk.finance.yahoo.com - December 23 at 11:14 PM
News for Calithera Biosciences IncNews for Calithera Biosciences Inc
markets.businessinsider.com - December 15 at 1:13 AM
Is CALA A Good Stock To Buy Now?Is CALA A Good Stock To Buy Now?
finance.yahoo.com - December 14 at 3:10 PM
Do Options Traders Know Something About Calithera (CALA) Stock We Dont?Do Options Traders Know Something About Calithera (CALA) Stock We Don't?
finance.yahoo.com - December 11 at 12:48 PM
Calithera Biosciences Poised For Long-Term SuccessCalithera Biosciences Poised For Long-Term Success
seekingalpha.com - November 25 at 3:31 AM
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 DayCalithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
finance.yahoo.com - November 11 at 11:53 AM
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual MeetingCalithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting
finance.yahoo.com - November 9 at 7:23 AM
Calithera Biosciences (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call TranscriptCalithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 11:27 AM
Calithera Biosciences EPS misses by $0.01Calithera Biosciences EPS misses by $0.01
seekingalpha.com - November 5 at 8:10 PM
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent HighlightsCalithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
finance.yahoo.com - November 5 at 8:10 PM
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)
finance.yahoo.com - November 4 at 1:35 PM
Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280
finance.yahoo.com - November 2 at 8:53 AM
What Is The Ownership Structure Like For Calithera Biosciences, Inc. (NASDAQ:CALA)?What Is The Ownership Structure Like For Calithera Biosciences, Inc. (NASDAQ:CALA)?
finance.yahoo.com - October 30 at 9:08 AM
Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
finance.yahoo.com - October 29 at 8:46 AM
Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual ConferenceCalithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference
markets.businessinsider.com - October 8 at 5:17 PM
Calithera launches mid-stage study of telaglenstat in lung cancerCalithera launches mid-stage study of telaglenstat in lung cancer
seekingalpha.com - September 24 at 12:40 PM
Calithera initiates mid-stage lung cancer study with telaglenastat in combination of immunotherapyCalithera initiates mid-stage lung cancer study with telaglenastat in combination of immunotherapy
seekingalpha.com - September 24 at 12:40 PM
Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung CancerCalithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer
finance.yahoo.com - September 24 at 7:39 AM
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.